First-generation COVID-19 vaccines have reduced efficacy against the emerging variants of SARS-CoV-2.
Partner with us to speed up the development of a Phase 2 clinical trial-ready second-generation vaccine which induces durable and strong neutralising antibody response through direct investment or licensing.
Second-generation COVID-19 vaccine which induces durable and strong neutralising antibody immunity activity against the original Wuhan SARS-CoV-2 strain as well as Beta, Delta and Omicron variants.
Safe and effective vaccines are critical in controlling the spread of COVID-19, which has claimed more than six million lives. Emerging mutant variants of SARS-CoV-2 are less susceptible to the immunity produced by the first generation COVID-19 vaccines.
The second-generation vaccine targets the receptor-binding domain region of the spike protein, compared to current vaccines that use antigens based on the full-length spike protein. This approach offers potential production and manufacturing advantages including the delivery of abundant, temperature-stable vaccine doses at an affordable cost.
Download flyer for more information (PDF)
Negotiating a licence with the University
By licensing the University of Melbourne’s intellectual property (IP) and technologies, you can harness research discoveries to solve business challenges.
Our IP principles
Our Intellectual Property (IP) management principles make it easier to collaborate with us.
Investing in University startups
Find out about new ways to invest in University startups
From developing an idea to finding startup funding, the University of Melbourne’s team of experts can help.